Skip to main content

Table 1 Differences in the baseline characteristics and clinical course of male and female participants

From: The impact of gender and the social determinants of health on the clinical course of people living with HIV in Myanmar: an observational study

Variable

Male

n = 138

Female

n = 83

p

Age

37 (31–46)

36 (33–44)

0.95

Unmarried

66 (48%)

40 (48%)

0.96

Unemployed

19 (14%)

34 (41%)

 < 0.001

Living outside Yangon

38 (28%)

16 (19%)

0.17

Did not complete high school

93 (68%)

60 (72%)

0.54

Number of family members living at home

3 (2–4)

3 (2–5)

0.90

Per-capita household income (USD)

46.15 (30.76–76.92)

51.28 (28.04–76.92)

0.90

Hazardous alcohol consumption

47/137 (34%)

0/83

 < 0.0001

Current cigarette smoker

54/128 (42%)

2/83 (2%)

 < 0.0001

Active injecting drug use

3/138 (2%)

0/83

0.29

Presently chewing betel nut

70/118 (59%)

7/82 (9%)

 < 0.0001

Hepatitis B surface antigen positive

15/127 (12%)

6/79 (8%)

0.48

Hepatitis C antibody positive

4/127 (3%)

2/79 (3%)

1.0

Body mass index (kg/m2)

19.3 (17.2–22.2)

18.9 (16.1–22.3)

0.29

Mean arm circumference (cm)

25 (22–27)

25 (22–27)

0.99

WHO stage at enrolment

1 (1–3)

2 (1–3)

0.02

CD4 cell count (cells/mm3)

92 (41–157)

92 (48–158)

0.61

Receiving dolutegravir containing regimen

117/137 (85%)

64/82 (78%)

0.16

Haemoglobin (g/dL)

12 (10–13.2)

10 (9–11)

0.0001

Creatinine (µmol/L)

95 (80–113)

80 (70–100)

0.0004

Dieda

6/138 (4%)

0/83

0.09

Hospitaliseda

2/138 (1%)

0/83

0.53

Died or hospitaliseda

8/138 (6%)

0/83

0.03

Lost to follow-upa

10/138 (7%)

6/83 (7%)

1.0

Detectable virusa

53/99 (54%)

20/61 (33%)

0.01

  1. All numbers represent absolute numbers (%) or median (interquartile range)
  2. aAt 6 months’ follow-up